These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3163908)

  • 1. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.
    Wexler HM; Finegold SM
    Antimicrob Agents Chemother; 1988 Apr; 32(4):601-4. PubMed ID: 3163908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter study of the in vitro antianaerobic activity of cefotetan compared with other antimicrobial agents.
    Zabransky RJ; Bobey DG; Sheikh W
    Am J Surg; 1988 May; 155(5A):47-51. PubMed ID: 3163901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of cefotetan against anaerobic bacteria.
    Watt B; Brown FV
    J Antimicrob Chemother; 1985 Jun; 15(6):671-7. PubMed ID: 3861604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cefotetan against anaerobic bacteria.
    Dias MB; Jacobus NV; Tally FP; Gorbach SL
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):359-63. PubMed ID: 3457672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
    Hoellman DB; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):495-501. PubMed ID: 9517922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefbuperazone against anaerobic bacteria.
    Wexler H; Carter WT; Harris BH; Finegold SM
    Antimicrob Agents Chemother; 1985 Apr; 27(4):674-6. PubMed ID: 3847274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative activity of 9 beta-lactamines, clindamycin and metronidazole on strictly anaerobic bacteria].
    Derriennic M; Reynaud A; Launay C; Courtieu AL
    Pathol Biol (Paris); 1987 May; 35(5):572-6. PubMed ID: 3302862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activity of cefotetan against anaerobic bacteria].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):643-4. PubMed ID: 2877431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.
    Shafran SD; Wong J; Chow AW
    Antimicrob Agents Chemother; 1985 May; 27(5):749-52. PubMed ID: 4015069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE; Gelfand M; Reller LB; Ayers LW; Pierson CL; Schoenknecht F; Tilton RC; Wilkins J; Henderberg A; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefbuperazone, a new cephamycin, against anaerobic bacteria.
    Prabhala RH; Thadepalli H; Rao B; Bansal MB; Marshall R
    Antimicrob Agents Chemother; 1985 Apr; 27(4):640-2. PubMed ID: 4004195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.